SCI journal
1. Wu WS, Chen YM, Tsai CM, et al: Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations. Exp Ther Med 3:207-213, 2012
2. Wu WS, Chen YM, Tsai CM, et al: The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-smallcell lung cancer. J Chin Med Assoc, 76:682-5, 2013
3. Wu WS, Wu CH, Lai SL, et al: Erlotinib salvage therapy in pulmonary adenocarcinoma patients with disease progression after previous EGFR-TKI treatment. Am J Clin Oncol, Jun 16, 2014. [Epub ahead of print]
4. Luo YH, Wu CH, Huang CY, Wu CW, Wu WS, et al. Brain metastasis features and association with tumor epidermal growth factor receptor mutation in patients with adenocarcinoma of the lung. Asia Pac J Clin Oncol. 2017 Oct;13(5):e440-e448.
5. Chang GC, Tseng CH, Hsu KH, Yu CJ, Yang CT, Chen KC, Yang TY, Tseng JS, Liu CY, Liao WY, Hsia TC, Tu CY, Lin MC, Tsai YH, Hsieh MJ, Wu WS, Chen YM. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.Lung Cancer. 2017 Feb;104:58-64
6. Shi Q, Li KJ, Treuer T, Wang BCM, Gaich CL, Lee CH, Wu WS, Furnback W, Tang CH. Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD).PLoS One. 2018 Apr 6;13(4):e0193489.
Review Article
1. Wu WS, Chen YM. Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance. J. Pers. Med. 2014, 4(3), 297-310
中文期刊
1. 吳⽂碩、邱鈺棋、賴信良、李毓芹 淋巴⾎血管平滑肌⾁肉增⽣生症 臨床醫學 2010; 65: 483-6
2. 吳⽂碩、黎俊義、陳育民、李毓芹 ⾮⼩細胞肺癌在同步化學及放射線治療後之腫瘤的組織病理學變化之特徵 臨床醫學 2010; 66: 234-40
3. 吳文碩、陳育民 ⾮⼩細胞肺癌的標靶治療新進展 臨床醫學 2012; 69: 338-43
沒有留言:
張貼留言